文献速递血管炎其他结缔组织病

土耳其与以色列儿童白塞病特征比较:一项横断面队列研究

Characteristics of pediatric Behçet's disease in Turkey and Israel: A cross-sectional cohort comparison.
PubMed 文献 · Semin Arthritis Rheum · 2020-02-04

该研究比较了土耳其和以色列儿童白塞病(BD)患者的特征,共纳入205例(土耳其165例,以色列40例)。土耳其患者HLA-B51阳性率、男性比例和皮肤受累更常见,且首次访视时BDCAF评分更高;以色列患者更多使用糖皮质激素、甲氨蝶呤和非甾体抗炎药。全组中ICBD标准敏感性最高(73.2%),秋水仙碱是最常用药物(96.6%)。

要点

  • 土耳其儿童BD患者HLA-B51阳性率、男性比例和皮肤受累显著高于以色列患者。
  • 全组中ICBD标准敏感性最高(73.2%),其次为PED-BD(47.8%)和ISG(42%)。
  • 以色列患者更常用糖皮质激素、甲氨蝶呤和非甾体抗炎药,土耳其患者首次访视BDCAF评分更高。

核心结论

  • 这是迄今报道的最大儿童白塞病队列,土耳其与以色列儿童BD患者的疾病特征存在显著差异,可能与不同种族和环境因素有关。

研究设计与样本

  • 横断面队列比较研究,纳入土耳其3个中心和以色列2个中心的205例儿童BD患者(土耳其165例,以色列40例),诊断年龄小于16岁且基于专家意见。

主要发现

  • 土耳其患者HLA-B51阳性率68.3% vs 以色列46.2%(p=0.028),男性比例52% vs 30%(p=0.012),皮肤受累55.2% vs 22.5%(p<0.001)。
  • 土耳其患者进行针刺试验和HLA-B51检测的比例更高(93.3% vs 32.5%,p<0.001;97.6% vs 65%,p<0.001)。
  • 全组ICBD标准敏感性最高(73.2%),其次为PED-BD(47.8%)和ISG(42%)。
  • 全组最常用药物为秋水仙碱(96.6%);以色列患者更常用糖皮质激素(50% vs 28.5%,p=0.006)、甲氨蝶呤(17.5% vs 3%,p=0.002)和非甾体抗炎药(12.5% vs 1.8%,p=0.007)。
  • 土耳其患者首次访视时BDCAF中位数更高(4 vs 2,p<0.001)。

关键数值与推荐

  • 儿童BD分类标准敏感性:ICBD 73.2%,PED-BD 47.8%,ISG 42%。
  • 土耳其患者HLA-B51阳性率68.3%,以色列46.2%(p=0.028)。
  • 土耳其患者男性比例52%,以色列30%(p=0.012)。
  • 土耳其患者皮肤受累55.2%,以色列22.5%(p<0.001)。
  • 土耳其患者首次访视BDCAF中位数4,以色列2(p<0.001)。

临床怎么用

  • 对于儿童疑似BD,ICBD标准敏感性最高,可优先考虑用于分类。
  • 土耳其与以色列儿童BD患者特征差异提示临床评估需考虑种族和环境因素。
  • 秋水仙碱是儿童BD最常用药物,以色列患者更常联合糖皮质激素、甲氨蝶呤和非甾体抗炎药。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Behçet's disease (BD) is a variable vessel vasculitis which is rare in children. OBJECTIVE: We aimed to compare the main characteristics of pediatric BD patients from Turkey versus Israel. METHODS: Three centers from Turkey and two centers from Israel participated in this study. The BD diagnosis was before 16 years of age and based on expert opinion. Disease activity was assessed with BD current activity form (BDCAF). RESULTS: A total of 205 patients were included (165 from Turkey; 40 from Israel). HLA-B51 positivity (68.3% vs. 46.2%, p = 0.028), male gender (52% vs. 30%, p = 0.012), and skin involvement (55.2% vs. 22.5%, p<0.001) were more frequent among patients from Turkey compared to patients from Israel. Tests of pathergy and HLA-B51 were more frequently performed in patients from Turkey than patients from Israel (93.3% vs. 32.5%, p<0.001 and 97.6% vs. 65%, p<0.001; respectively). For BD classification in the whole group, International Criteria for BD (ICBD) had the highest sensitivity (73.2%), followed by pediatric BD (PED-BD) (47.8%), and The International Study Group (ISG) (42%) criteria sets. The most commonly prescribed drug was colchicine in the whole group (96.6%). Significantly more patients were treated with corticosteroids (50% vs. 28.5%, p = 0.006), methotrexate (17.5% vs. 3%, p = 0.002), and nonsteroidal anti-inflammatory drugs (12.5% vs. 1.8%, p = 0.007) in Israel than in Turkey. The median BDCAF values were higher at the first visit for patients from Turkey compared to those in Israel (4 vs. 2, p<0.001). CONCLUSION: This is the largest cohort of pediatric BD reported to date. The disease characteristics significantly differ among pediatric BD patients from Turkey and Israel, which may be due to different ethnicity and environmental factors.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Butbul Aviel Y, Batu ED, Sözeri B, et al. Characteristics of pediatric Behçet's disease in Turkey and Israel: A cross-sectional cohort comparison. Semin Arthritis Rheum. 2020. PMID: 32113838. doi:10.1016/j.semarthrit.2020.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。